Mariann Polgar-Turcsanyi, M.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 14 | 2024 | 3213 | 0.920 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 6 | 2024 | 253 | 0.870 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2024 | 564 | 0.460 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 4 | 2023 | 550 | 0.420 |
Why?
|
| Neurofilament Proteins | 3 | 2023 | 336 | 0.260 |
Why?
|
| Atrophy | 4 | 2021 | 1629 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2023 | 3784 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 841 | 0.110 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 171 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 2223 | 0.090 |
Why?
|
| Brain | 7 | 2023 | 27178 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2023 | 36537 | 0.080 |
Why?
|
| Information Management | 1 | 2005 | 100 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3359 | 0.050 |
Why?
|
| Disease Progression | 4 | 2024 | 13614 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 605 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 198 | 0.050 |
Why?
|
| Stroke | 1 | 2023 | 9747 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2015 | 5088 | 0.040 |
Why?
|
| Male | 12 | 2024 | 363585 | 0.040 |
Why?
|
| Adult | 10 | 2024 | 222974 | 0.040 |
Why?
|
| Female | 12 | 2024 | 395961 | 0.040 |
Why?
|
| Humans | 18 | 2024 | 765734 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 1003 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2021 | 820 | 0.030 |
Why?
|
| Middle Aged | 7 | 2024 | 222903 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2024 | 1585 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3211 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4779 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2024 | 81457 | 0.020 |
Why?
|
| Incidence | 2 | 2024 | 21478 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3427 | 0.020 |
Why?
|
| Quality of Life | 2 | 2022 | 13462 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 979 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 8926 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 54795 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2023 | 41631 | 0.010 |
Why?
|
| Neurons | 1 | 2022 | 9521 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2859 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1472 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26284 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3339 | 0.010 |
Why?
|
| Adolescent | 2 | 2023 | 88781 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14745 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2005 | 1404 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20120 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 12509 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 81792 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18375 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 59852 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 8730 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 168731 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 39180 | 0.000 |
Why?
|
| Aged | 1 | 2017 | 171050 | 0.000 |
Why?
|